Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Δευτέρα 19 Δεκεμβρίου 2016

Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber

alertIcon.gif

Publication date: January 2017
Source:Annals of Allergy, Asthma & Immunology, Volume 118, Issue 1
Author(s): Robert L. Jacobs, Daniel A. Ramirez, Cynthia G. Rather, Charles P. Andrews, Daniel C. Jupiter, Fernando Trujillo, David G. Shulman
BackgroundThere are few direct data concerning symptom dynamics of allergic conjunctivitis (AC) in an allergen challenge chamber (ACC).ObjectiveTo determine the AC dynamics on subsequent exposures to ragweed pollen (RW) in individuals with allergic rhinitis in an ACC. To determine whether consecutive exposures in an ACC have any persistent detrimental ocular physical effects.MethodsParticipants underwent 3 exposures to RW in an ACC. Ocular symptoms of itching and tearing were self-assessed. Ocular redness and lid swelling were assessed by trained ophthalmic technicians. Complete ophthalmic examinations (COEs) were performed by an ophthalmologist.ResultsA total of 188 of 201 participants (93%) developed an ocular redness score of 2 or more in each eye in ACC exposure 1. Reproducibility of redness occurred in approximately 70% of individuals completing ACC exposures 1 through 3. There were no significant changes between baseline COE and end of study COE. Phenotypes were identified by redness responses during and after exposure. Baseline total ocular symptom scores, at 24 hours after a priming exposure, were identified as late-phase reactions rather than enhanced sensitivity.ConclusionWhen assessed by trained professionals, AC was present with a very high frequency in selected individuals allergic to RW monitored in an ACC. Intrasubject reproducibility of redness was consistent across 3 ACC allergen exposures. Phenotypes were identified as early-phase responses, protracted early-phase responses, dual responses, and late-phase responses.Trial Registrationclinicaltrials.gov Identifier: NCT02079649.



http://ift.tt/2hRy9jA

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου